Abstract:Aim: Silent information regulator two homologue one (SIRT1) is an emerging target for managing metabolic disorders. This study aimed to synthesize novel 5-(- substituted phenyl)-2-aryl benzimidazole derivatives and evaluate them for SIRT1 activation. Methods: The compounds were designed according to the findings of the QSAR models framed in our previous studies. Molecular docking and dynamics studies were also performed to explore the interactions of designed compounds with the active site of the SIRT1 enzyme using AutoDock Vina and Schrödinger Maestro version 11.8.012, respectively. Compounds with good binding affinity were synthesized by Suzuki-Miyaura cross-coupling and spectrally characterized. The molecules were evaluated for their in vitro SIRT1 activation properties using a fluorescent screening kit. Based on the results of in vitro assay, a structure-activity relationship was established. SwissADME was employed to calculate the pharmacokinetics characteristics of the synthesized molecules. Results: The molecular docking studies revealed that all the activators were effectively docked in the catalytic active site. All compounds demonstrated interactions with important amino acids like Glu230 and Arg446. In molecular dynamics simulations, the root mean square deviation (RMSD) of compound 5m and protein SIRT1 remained stable, i.e., below 3mm. Compound 5m, 4-(2-(3,4-dihydroxy-5-nitrophenyl)-1H-benzo[d]imidazol- 5-yl)benzaldehyde, was the most potent compound with an EC50 value of 0.006 mM (±0.001) and maximum activation of 240.5%. All the synthesized compounds had acceptable theoretical ADME profiles, and drug-likeness properties complied with Lipinski's rule. Conclusion: According to the findings, synthesized compounds may be viable leads for SIRT1 activators and may be used to advance preclinical in vivo research utilizing animal models.

The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.

The Discovery of Novel 10,11-Dihydro-5h-dibenz[b,f]azepine SIRT2 Inhibitors.

Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-n-phenylacetamide Derivatives As New Potent and Selective Human Sirtuin 2 Inhibitors

Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis

Thienopyrimidinone Based Sirtuin-2 (Sirt2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket.

Symmetrical 2,7‐disubstituted 9H‐fluoren‐9‐one as a novel and promising scaffold for selective targeting of SIRT2

Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure–Activity Relationship, X-ray Crystal Structure, and Anticancer Activity

Pharmacophore-guided in-silico discovery of SIRT1 inhibitors for targeted cancer therapy

X-ray Crystal Structure Guided Discovery of New Selective, Substrate-Mimicking Sirtuin 2 Inhibitors That Exhibit Activities Against Non-Small Cell Lung Cancer Cells.

Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors

Design, synthesis and biological evaluation of 2,4,6- trisubstituted triazine derivatives as new nonpeptide small-molecule SIRT5 inhibitors

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

2‐(Methyl(phenyl)amino)‐N‐(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition

In silico drug discovery of SIRT2 inhibitors from natural source as anticancer agents

Discovery of 5-(Substituted Phenyl)-2-aryl Benzimidazole Derivatives as SIRT1 Activators: Their Design, in silico Studies, Synthesis, and in vitro Evaluation

Discovery of Resorcinol-Based Polycyclic Structures As Tyrosinase Inhibitors for Treatment of Parkinson's Disease

Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors

Molecular Modeling, Chemical Synthesis and Biological Assays

Discovery of Indolylpiperazinylpyrimidines with Dual-Target Profiles at Adenosine A2A and Dopamine D2 Receptors for Parkinson's Disease Treatment.

Sirt2 Enhances 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Mptp)-Induced Nigrostriatal Damage Via Apoptotic Pathway

Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells